RIBOCICLIB
Manufacturer: Novartis Pharmaceuticals Corporation
Score: 141.0
KISQALI (ribociclib) is a kinase inhibitor used in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence, and for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant. Key clinical findings include increased progression-free survival and overall survival in patients with advanced or metastatic breast cancer. Important safety information includes warnings for interstitial lung disease/pneumonitis, severe cutaneous adverse reactions, QT interval prolongation, hepatobiliary toxicity, and neutropenia. The recommended starting dose is 400 mg orally once daily for 21 consecutive days followed by 7 days off treatment for early breast cancer, and 600 mg orally once daily for 21 consecutive days followed by 7 days off treatment for advanced or metastatic breast cancer. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use.
Interstitial lung disease/pneumonitis, severe cutaneous adverse reactions, QT interval prolongation, hepatobiliary toxicity, and neutropenia
Dose interruptions, reductions, and discontinuations may be necessary based on individual patient safety and tolerability
400 mg orally once daily for 21 consecutive days followed by 7 days off treatment
Not applicable
600 mg orally once daily for 21 consecutive days followed by 7 days off treatment
Not applicable
ABEMACICLIB
Eli Lilly and Company
NERATINIB
Puma Biotechnology, Inc.
TRASTUZUMAB-DKST
Biocon Biologics Inc.
LENVATINIB
Eisai Inc.
PRALSETINIB
Genentech, Inc.
PRALSETINIB
Rigel Pharmaceuticals, Inc.